13th European Headache Congress

Migraine does not take lives but days from your life. Take them back!

e- Posters

Notification to authors regarding the posters has already been sent. In case you have not received an e-mail from the Organizing Committee, please contact Lydia Makropoulou at [email protected]

 

e-Poster Presentation Session 1: 

Clinical Trials

Chairs: Dr. Theodoros S. ConstantinidisDr. Emmanouil Dermitzakis 

e-Poster 001       

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMG 301 IN MIGRAINE PREVENTION
Messoud Ashina,1 David Doležil,2 Jo H. Bonner,3 Lifen Zhou,4 Jan Klatt,5 Hernan Picard,4 Daniel D. Mikol4
1Rigshospitalet Glostrup, Glostrup, Denmark, 2DADO MEDICAL sro, Prague Headache Center, Prague, Czech Republic, 3Mercy Research, Saint Louis, MO, USA, 4Amgen Inc., Thousand Oaks, CA, USA, 5Novartis Pharma AG., Basel, Switzerland

e-Poster 002       

ERENUMAB AND GALCANEZUMAB IN CHRONIC MIGRAINE PREVENTION: EFFECTS AFTER TREATMENT DISCONTINUATION
Bianca Raffaelli*, Valeria Mussetto, Heike Israel, Lars Neeb, Uwe Reuter
Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

e-Poster 003       

OBSERVATIONAL, OPEN-LABEL, NON-RANDOMIZED STUDY ON THE EFFICACY OF ONABOTULINUMTOXINA IN THE TREATMENT OF NUMMULAR HEADACHE: SERIES OF 38 PATIENTS
García-Azorín, A. Sierra, J. Trigo, E. Martínez-Pías, Al. Guerrero
Headache Unit, Neurology Department. Hospital Clínico Universitario, Valladolid, Spain

e-Poster 004       

HOW ADVERSE EVENTS ARE COLLECTED AND REPORTED: DIFFERENCES BETWEEN RANDOMIZED PHASE 2 AND PHASE 3 CLINICAL TRIALS FOR LASMIDITAN
David. Kudrow1, John H. Krege2, Rashna Khanna3, Hans P. Hundemer4, Paul H. Berg2, Michael H. Ossipov5, Patricia Pozo-Rosich6,7
1California Medical Clinic for Headache, Santa Monica, CA, USA and Assistant Clinical Professor in Neurology at the David Geffen UCLA School of Medicine, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Eli Lilly and Company, Erl Wood, United Kingdom, 4Eli Lilly and Company, Bad Homburg, Germany, 5Syneos Health, Clinical Division, Raleigh, NC, USA, 6Headache & Craniofacial Pain Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain, 7Headache Research Group, VHIR, Universitat Autònoma de Barcelona, Barcelona, Spain

e-Poster 005       

SAFETY FINDINGS FROM THE PHASE 3 STUDIES (SAMURAI, SPARTAN) OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE
John H. Krege1, Paul Rizzoli2, Emily Liffick, Erin G. Doty, Sherie A. Dowsett1, Jia Ning Wang1, Andrew S. Buchanan1
1Eli Lilly and Company, Indianapolis, IN, 2Brigham and Women's Faulkner Hospital, Boston, MA
 
e-Poster 006       

QUARTERLY ADMINISTRATION OF FREMANEZUMAB DOES NOT SHOW “WEARING OFF” EFFECT DURING THIRD MONTH AFTER INJECTION
Cory A. Blaiss, Darko Stevanovic, Joshua M. Cohen, Ronghua Yang, Bo Jiang, Nicholas Gross
Teva Pharmaceuticals, Frazer, Pennsylvania, USA
 
e-Poster 007       

COMPARISON OF RESPONDER RATES BETWEEN FREMANEZUMAB, ERENUMAB AND ONABOTULINUMTOXINA AMONG PATIENTS WITH MIGRAINE WITH ≥3 PRIOR TREATMENT FAILURES: A NETWORK META-ANALYSIS
Oscar Patterson-Lomba1, Rajeev Ayyagari1, Stephen Thompson2, Sanjay Gandhi2, Stephanie Bousleiman1, Ronghua Yang2, Yao Wang1, Joshua Cohen2
1Analysis Group, Inc., Boston, MA,  2Teva Pharmaceuticals
 
e-Poster 008       

LONG-TERM IMPACT OF FREMANEZUMAB ON HEADACHE-RELATED DISABILITY AND QUALITY OF LIFE IN PATIENTS WHO REVERTED FROM A CHRONIC TO AN EPISODIC MIGRAINE CLASSIFICATION
Jessica Ailani1, Joshua M. Cohen2, Marianna S. Yugrakh3, Xiaoping Ning2
1Medstar Georgetown University Hospital, Washington, District of Columbia, USA, 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA, 3Headache Center, Department of Neurology, Columbia University Medical Center, New York, USA

e-Poster 009       

LONG-TERM SAFETY OF FREMANEZUMAB: RESULTS OF A 1-YEAR STUDY
Xiaoping Ning1, Joshua M. Cohen, Nathan Bennett2, Ronghua Yang1
1Teva Pharmaceuticals, Frazer, Pennsylvania, USA, 2Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, USA
 
e-Poster 010       

LONG-TERM IMPACT OF FREMANEZUMAB ON RESPONSE RATES: RESULTS OF A 1-YEAR STUDY
Lawrence C. Newman1, Joshua M. Cohen2, Ronghua Yang2, Xiaoping Ning2
1New York University Langone Health, New York, USA , 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA
 
e-Poster 011       

LONG-TERM EFFICACY OF FREMANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE WITH CONCOMITANT PREVENTIVE MEDICATION USE
Peter J. Goadsby1, Adelene E. Jann2, Joshua M. Cohen3, Ronghua Yang3, Xiaoping Ning3
1NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, UK, 2Department of Neurology, NYU Langone Health, New York, New York, USA, 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA
 
e-Poster 012       

LONG-TERM EFFICACY OF FREMANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE AND COMORBID MODERATE TO SEVERE DEPRESSION
Richard B. Lipton1,2, Joshua M. Cohen3, Ronghua Yang3, XXiaoping Ning3, Dawn  C. Buse1
1Albert Einstein College of Medicine, Bronx, New York, USA, 2Montefiore Medical Center, Bronx, New York, USA, 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA

e-Poster 013       

LONG-TERM IMPACT OF FREMANEZUMAB ON RESPONSE RATES, ACUTE HEADACHE MEDICATION USE, AND DISABILITY IN PATIENTS WITH CHRONIC MIGRAINE: RESULTS OF A 1-YEAR STUDY
Peter McAllister1, Joshua M. Cohen2, Sanjay K. Gandhi2, Ronghua Yang2
1New England Institute for Neurology and Headache, Stamford, Connecticut, USA, 2Teva Pharmaceuticals, Frazer, Pennsylvania, USA

e-Poster 014       

LONG-TERM IMPACT OF FREMANEZUMAB ON HEADACHE-RELATED DISABILITY, QUALITY OF LIFE, AND PATIENT SATISFACTION IN EPISODIC MIGRAINE AND CHRONIC MIGRAINE
Joshua M. Cohen1, Nicolas P. Saikali2, Ronghua Yang1, Xiaoping Ning1
1Teva Pharmaceuticals, Frazer, Pennsylvania, USA, 2Dent Neurologic Institute, Buffalo, New York, USA
 
e-Poster 015       

LONG-TERM EFFICACY AND SAFETY OF FREMANEZUMAB IN MIGRAINE: RESULTS OF A 1-YEAR STUDY
Peter J. Goadsby1, Teshamae Monteith2, Joshua M. Cohen3, Ronghua Yang3
1NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, UK, 2Headache Division, Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, USA, 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA
 
e-Poster 016       

IMPROVEMENT IN RESPONSE OVER TIME WITH FREMANEZUMAB IN PATIENTS WHO REVERTED FROM A CHRONIC TO AN EPISODIC MIGRAINE CLASSIFICATION
Rashmi B. Halker Singh1, Michael J. Marmura2, Joshua M. Cohen3, Ronghua Yang3
1Mayo Clinic, Phoenix, Arizona, USA, 2Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA
 
e-Poster 017       

REDUCTION IN MONTHLY MIGRAINE DAYS (MMDS) WITH FREMANEZUMAB AND ERENUMAB AMONG PATIENTS WITH EPISODIC MIGRAINE (EM) WITH 2-4 PRIOR TREATMENT FAILURES: A NETWORK META-ANALYSIS
Fan Mu1, Oscar Patterson-Lomba1, Stephen Thompson2, Sanjay Gandhi2, Tahera Doctor1, Joshua Cohen2, Akanksha Dua1, Ronghua Yang2
1Analysis Group, Inc., Boston, MA, 2Teva Pharmaceuticals
 
e-Poster 018       

REDUCTION IN MONTHLY MIGRAINE DAYS (MMDS) WITH FREMANEZUMAB AND ERENUMAB AMONG PATIENTS WITH CHRONIC MIGRAINE (CM) WITH 2 TO 4 PRIOR TREATMENT FAILURES: A NETWORK META-ANALYSIS
Rajeev Ayyagari1, Fan Mu1, Stephen Thompson2 , Akanksha Dua1, Ronghua Yang2, Yao Wang1, Joshua Cohen2, Sanjay Gandhi2
1Analysis Group, Inc., Boston, MA, USA, 2Teva Pharmaceuticals
 
e-Poster 019       

LONG-TERM IMPACT OF FREMANEZUMAB ON RESPONSE RATES, ACUTE HEADACHE MEDICATION USE, AND DISABILITY IN PATIENTS WITH EPISODIC MIGRAINE: RESULTS OF A 1-YEAR STUDY
Jan Lewis Brandes1, Michael J. Marmura2, Joshua M. Cohen3, Sanjay K. Gandhi3, Ronghua Yang3
1Nashville Neuroscience Group, Vanderbilt University, Department of Neurology, Nashville, Tennessee, USA, 2Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, 3Teva Pharmaceuticals, Frazer, Pennsylvania, USA

e-Poster 020       

EFFICACY OF FREMANEZUMAB IN PATIENTS WITH MIGRAINE AND DOCUMENTED INADEQUATE RESPONSE TO 2, 3, OR 4 CLASSES OF MIGRAINE PREVENTIVE TREATMENTS: RESULTS OF THE INTERNATIONAL, MULTICENTER, RANDOMISED, PLACEBO-CONTROLLED FOCUS STUDY
Ladislav Pazdera1, Xiaoping Ning2, Maja Galic3, Joshua M. Cohen2, Ronghua Yang2
1Vestra Clinics, Rychnov nad Kněžnou, Czech Republic, 2Teva Pharmaceuticals Industries, Frazer, PA, USA, 3Teva Pharmaceuticals, Amsterdam, The Netherlands
 
e-Poster 021       

IMPACT OF AGE AND SEX ON EFFICACY OF FREMANEZUMAB IN PATIENTS WITH MIGRAINE AND DOCUMENTED INADEQUATE RESPONSE TO 2-4 CLASSES OF MIGRAINE PREVENTIVE TREATMENTS: RESULTS OF THE INTERNATIONAL, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED FOCUS STUDY
Antoinette MaassenVanDenBrink,1 Maja Galic,2 Joshua M. Cohen,3 Xiaoping Ning,3 Ronghua Yang,3 Verena Ramirez-Campos3
1Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Rotterdam, The Netherlands, 2Teva Pharmaceuticals, Amsterdam, The Netherlands, 3Teva Pharmaceuticals Industries, Frazer, PA, USA
 
e-Poster 022       

EARLY ONSET OF RESPONSE TO FREMANEZUMAB IN PATIENTS WITH MIGRAINE AND A DOCUMENTED INADEQUATE RESPONSE TO 2-4 CLASSES OF MIGRAINE PREVENTIVE TREATMENTS: RESULTS OF THE INTERNATIONAL, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED FOCUS STUDY
Egilius L.H. Spierings,1 Martina Machkova,2 Xiaoping Ning,3 Maja Galic,4 Joshua M. Cohen,3 Ronghua Yang3
1Medvadis Research Corporation, Watertown, MA, USA, 2CCR Czech Prague, Prague, Czech Republic, 3Teva Pharmaceuticals Industries, Frazer, PA, USA, 3Teva Pharmaceuticals, Amsterdam, The Netherlands
 
e-Poster 023       

HEALTHCARE RESOURCE UTILIZATION IN ADULT PATIENTS TREATED WITH ONABOTULINUMTOXINA FOR CHRONIC MIGRAINE: RESULTS FROM THE COMPEL STUDY
John F. Rothrock, MD1, Richard Stark, MB, BS, FRACP2, Katherine Sommer, PhD3, Andrew M. Blumenfeld, MD4
1George Washington University School of Medicine, Washington, DC, USA, 2Alfred Hospital and Monash University, Melbourne, Australia, 3Allergan plc, Marlow, UK, 4Headache Center of Southern California, The Neurology Center, Carlsbad, CA, USA
 
e-Poster 024       

ONSET OF EFFICACY FOLLOWING ORAL TREATMENT WITH LASMIDITAN FOR THE ACUTE TREATMENT OF MIGRAINE
Messoud Ashina1, Raghavendra Vasudeva2, Leah Jin3, Louise Lombard2, Elizabeth Gray4, Erin G. Doty2, Laura Yunes-Medina2, Kraig S. Kinchen2, Cristina Tassorelli5,6
1University of Copenhagen, Copenhagen, Denmark, 2Eli Lilly and Company, Indianapolis, IN, USA; 3Covance Chiltern, Princeton, New Jersey, USA; 4Eli Lilly Canada Inc, Toronto, ON, Canada, 5University of Pavia, Pavia, Italy; 6Headache Science Centre, IRCCS Mondino Foundation
 
e-Poster 025       

EFFECT OF AGE ON EFFICACY AND SAFETY OF GALCANEZUMAB TREATMENT IN ADULT PATIENTS WITH MIGRAINE
Virginia L. Stauffer1, Ira Turner2, Phebe Kemmer1, Martha Port1, Kathleen Day1, Angelo Camporeale3
1Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA, 2Center for Headache Care and Research, Island Neurological Associates, Plainview, NY, USA, 3Eli Lilly Italia, Sesto Fiorentino, Italy

e-Poster 026       

GALCANEZUMAB SIGNIFICANTLY REDUCED HEALTHCARE RESOURCE UTILIZATION AND ACUTE MEDICATION USE IN PATIENTS WITH CHRONIC MIGRAINE: FINDINGS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION 
Shivang Joshi1, Joshua A. Tobin2, Janet H. Ford3, Russell Nichols3, Shonda A. Foster3, Dustin Ruff3, Holland C. Detke3, Sheena K. Aurora3
1Dent Neurologic Institute, Amherst, New York and University of Buffalo School of Pharmacy, Buffalo, NY, USA, 221st Century Neurology, Phoenix, AZ, USA, 3Eli Lilly and Company, Indianapolis, IN, USA
 
e-Poster 027       

CONSISTENT REDUCTIONS IN MIGRAINE FREQUENCY WITH EPTINEZUMAB TREATMENT IN PATIENTS WITH MIGRAINE STRATIFIED BY INTRINSIC FACTORS: SUBGROUP ANALYSES OF PROMISE-1 AND PROMISE-2
Marina Janelidze1, Gvantsa Giorgadze2, Roger Cady3, Steve Snapinn3, Joe Hirman4, Eric Kassel3
1Department of Neurology, Tbilisi State Medical University, Tbilisi, Republic of Georgia, 2Department of Neurology, LTD Aversi Clinic, Tbilisi, Republic of Georgia, 3Alder BioPharmaceuticals, Inc., Bothell, WA, USA, 4Pacific Northwest Statistical Consulting, Inc., Woodinville, WA, USA
 
e-Poster 028       

CONSISTENT REDUCTIONS IN MIGRAINE FREQUENCY WITH EPTINEZUMAB TREATMENT IN PATIENTS WITH MIGRAINE STRATIFIED BY DISEASE CHARACTERISTICS: SUBGROUP ANALYSIS OF PROMISE-1 AND PROMISE-2
George Chakhava1, Roger Cady2, Eric Kassel2, Joe Hirman3, Steve Snapinn2
1Multiprofile Clinic Consilium Medulla, Georgian Association of Medical Specialties, Tbilisi, Republic of Georgia, 2Alder BioPharmaceuticals, Inc., Bothell, WA, USA, 3Pacific Northwest Statistical Consulting, Inc., Woodinville, WA, USA

e-Poster 029       

EPTINEZUMAB FOR THE PREVENTION OF EPISODIC MIGRAINE THROUGH 1 YEAR: RESULTS FROM THE PHASE 3 PROMISE-1 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY‒1) TRIAL
Messoud Ashina1, Timothy R. Smith2, George Chakhava3, Roger Cady4, Barbara Schaeffler4, David Biondi4, Joe Hirman5, Jeff Smith6
1Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark, 2StudyMetrix Research, Saint Peters, MO, USA, 3Multiprofile Clinic Consilium Medulla, Georgian Association of Medical Specialties, Tbilisi, Republic of Georgia, 4Alder BioPharmaceuticals, Inc., Bothell, WA, USA, 5Pacific Northwest Statistical Consulting, Inc., Woodinville, WA, USA, 6Alder BioPharmaceuticals, Ltd., Dublin, Ireland
 
e-Poster 030       

SHIFT FROM CHRONIC MIGRAINE TO EPISODIC MIGRAINE STATUS IN A LONG-TERM PHASE 3 STUDY OF GALCANEZUMAB
Holland Detke1, Kathleen A Day1, Sarah Lipsius2, Sheena K Aurora1, Nada A. Hindiyeh3, Hans-Christoph Diener4
1Eli Lilly and Company, Indianapolis, IN, USA, 2 Syneos Health, Raleigh, NC, USA, 3Stanford University School of Medicine, Stanford, USA, 4Faculty of Medicine, University Duisburg-Essen, Essen, Germany

e-Poster 031       

THE IMPACT OF ONABOTULINUMTOXINA VS PLACEBO ON EFFICACY OUTCOMES IN RESPONDER AND NONRESPONDER SUBGROUPS OF PATIENTS WITH CHRONIC MIGRAINE: PREEMPT POOLED ANALYSIS
Hans-Christoph Diener1, Richard B. Lipton2, David W. Dodick3, Ronald E. DeGryse4, Aubrey Manack Adams4, Stephen Silberstein5
1Faculty of Medicine, University of Duisbury-Essen, Essen, Germany, 2Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA, 3Department of Neurology, Mayo Clinic, Phoenix, AZ, USA, 4Allergan plc, Irvine, CA, USA, 5Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA
 
e-Poster 032       

SHORT AND MID-TERM PREDICTORS OF RESPONSE TO ONABOTULINUMTOXINA: A PRACTICAL APPROACH FROM A SPANISH HEADACHE SPECIALIZED UNIT
A.Alpuente1,2, VJ. Gallardo2, M.Torres-Ferrús1,2, J.Álvarez-Sabín1, P.Pozo-Rosich1
1 Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 2 Headache  Research  Group,  Vall  d'Hebron  Research  Institute  (VHIR),  Universitat, Autònoma de Barcelona, Barcelona, Spain

e-Poster Presentation Session 2

Clinical Trials and Animal-Human studies

Chairs: Dr. Mark BraschinskyDr. Ermioni Giannouli 

e-Poster 033       

A UNIQUE ANDROGEN EXCESS SIGNATURE IN IDIOPATHIC INTRACRANIAL HYPERTENSION IS LINKED TO CEREBROSPINAL FLUID DYNAMICS
Michael W. O'Reilly, Connar S.J. Westgate, Catherine Hornby, Hannah Botfield, Angela E. Taylor, Keira Markey, James L. Mitchell, William J. Scotton, Susan P. Mollan, Andreas Yiangou, Carl Jenkinson, Lorna C. Gilligan, Mark Sherlock, James Gibney, Jeremy W. Tomlinson, Gareth G. Lavery, David J. Hodson, Wiebke Arlt, and Alexandra J. Sinclair
 
e-Poster 034       

ONABOTULINUMTOXINA AFFECTS VISUAL CORTICAL EXCITABILITY IN CHRONIC MIGRAINEURS: PRELIMINARY RESULTS OF A STUDY WITH SOUND INDUCED FLASH ILLUSIONS
Angelo Torrente§, Massimo Gangitano§, Salvatore Di Marco§, Laura Pilati§, Salvatore Ferlisi§, Serena Scardina§, Erika Di Marco§, Fabiola Ferraro§, Lavinia Vassallo§, Giuseppe La Bianca§, Giuseppe Cosentino*, Filippo Brighina§
Department of Biomedicine, Neurosciences and Diagnostic (Bi.N.D.), University of Palermo, Italy, *Istituto Neurologico Nazionale a Carattere Scientifico Fondazione Mondino, Pavia, Italy

e-Poster 035       

DIFFERENCES IN SEX HORMONE LEVELS BETWEEN FEMALE MIGRAINE PATIENTS AND HEALTHY CONTROLS
Daphne S. van Casteren1,2*, Alejandro Labastida-Ramirez1, Tobias Kurth3, Gisela M. Terwindt2,#, Antoinette Maassen van den Brink1,#
1Dept. Of Internal Medicine, Div. of Pharmacology, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands, 2Dept. Of Neurolo gy, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands, 3Institute of Public Health, Charité – Universitätsmedizin Berlin, Berlin, Germany, * Corresponding author: [email protected], # Shared last author

e-Poster 036   
    

PAIN EXTENT IS NOT RELATED TO WIDESPREAD PRESSURE PAIN SENSITIVITY IN MEN WITH EPISODIC CLUSTER HEADACHE
García-Azorín1, S. Fuensalida-Novo2, M. Palacios-Ceña2, D. Falla3, V. Gómez-Mayordomo4, ML. Cuadrado4, AL. Guerrero1, C. Fernández-de-las-Peñas2, M. Barbero5
1Headache Unit. Hospital Clínico Universitario de Valladolid, Spain, 2Departamento de Fisioterapia, Terapia Ocupacional, Rehabilitación y Medicina Física. Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain, 3School of Sport, Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham, UK, 4Neurology Department. Universidad Complutense de Madrid, Spain, 5Rehabilitation Research Laboratory 2rLab, Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland
 
e-Poster 037       

CENTRAL SENSITIZATION IN MEN WITH EPISODIC CLUSTER HEADACHE
García-Azorín D1, Palacios-Ceña M2, Gómez-Mayordomo V3, Fuensalida-Novo S2, González-García N3, Guerrero AL1, Cuadrado ML3, Fernández-de-las-Peñas C2
1Headache Unit. Hospital Clínico Universitario de Valladolid, Spain, 2Departamento de Fisioterapia, Terapia Ocupacional, Rehabilitación y Medicina Física. Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain, 3Neurology Department. Universidad Complutense de Madrid, Spain

e-Poster 038       

COMPARING BENEFIT-RISK PROFILES OF ANTI-CGRP ΜONOCLONAL ΑNTIBODIES FOR ΜIGRAINE PREVENTION: A LIKELIHOOD TO HELP VS. HARM (LHH) ANALYSI
K. Drellia1*, L. Kokoti1*, D. Papadopoulos2, D.D. Mitsikostas1
1Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens,  Athens, Greece, 2Neurology Clinic, Athens Medical Center-Paleo Phaliro Clinic, Athens, Greece, *equally contributed

e-Poster 039       

DIGITAL THERAPEUTICS NEUROMODULATION FOR MIGRAINE
Oved Daniel1, Eran Chenker2,3  
1Headache & Facial Pain Clinic Director. Ramat Aviv Medical Center. Tel Aviv, Israel, 2Management of Health Informatics and Analytics program. Milken Institute School of Public Health. George Washington University. Washington, USA, 3 Neurolief, Netanya, Israel

e-Poster 040       

RATIONALE AND DESIGN FOR A RANDOMISED MULTICENTRE STUDY FOR THE PREVENTION AND ACUTE TREATMENT OF MIGRAINE USING OPEN-LABEL NON-INVASIVE VAGUS NERVE STIMULATION VERSUS STANDARD OF CARE (THE REAL STUDY)
Alexandra Sinclair1; Charly Gaul2; Cristina Tassorelli3; Eric Liebler4; Miguel Làinez5
1Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK, 2Migraine and Headache Clinic, Königstein, Germany, 3National Neurological Institute C. Mondino Foundation, Pavia, Italy, 4electroCore, Inc., Basking Ridge, New Jersey, USA, 5University Clinic Hospital, Catholic University of Valencia, Valencia, Spain

e-Poster 041       

RATIONALE AND DESIGN FOR A RANDOMISED, SINGLE-CENTRE, DOUBLE-BLIND, SHAM-CONTROLLED STUDY OF NON-INVASIVE VAGUS NERVE STIMULATION FOR THE ACUTE AND PREVENTIVE TREATMENT OF POST-TRAUMATIC HEADACHE
Bert Vargas1*; Eric Liebler2; Stephen Bunt1; Charlene Supnet1
1University of Texas Southwestern Medical Center, Dallas, Texas , 2electroCore, Inc., Basking Ridge, New Jersey, USA, 

e-Poster 042       

IMPACT OF MIGRAINE ON DAILY ACTIVITIES: A STRATIFIED ANALYSIS BY MONTHLY MIGRAINE DAY 
C.Silva1, P. Vo2, F. Costa1, J. Parreira1, R. Quintana3,4, V. Carboni5, PA Laires1
1Novartis Farma, Portugal, 2Novartis Pharma AG, Switzerland, 3GfK Health, Switzerland, 4GfK EMER, Spain, 5IPSOS, Switzerland
 
e-Poster 043       

EFFECTS OF PROLONGED TREATMENT WITH SINGLE PULSE TRANSCRANIAL MAGNETIC STIMULATION (STMS) iN ANIMAL models of migrain
M. Jones, S. McMahon, R. Abuukar Abdullahi, Dr G Lambru, AP. Andreou

e-Poster 044       

APPLICATION OF  MICRO-CAUTERISATION (ON CERVICAL,OCCIPITAL AND TEMPORAL AREAS) FOR PATIENTS WITH CHRONIC MIGRAINE & HEADACHE DUE TO MEDICALTION OVERUSE (MOH). REPORT OF 21 CASES 
E.Papageorgiou, K. Kovas

e-Poster 045       

INTRADERMAL ADMINISTRATION OF BOTULINUM TOXIN TYPE A (BTX-A) IN PATIENTS WITH TRIGEMINAL NEURALGIA
R. Perez-Esteban, P. Baena-Palomino, R. Lamas-Perez, L. Munoz-Delgado, MD. Jimenez-Hernandez, MC. Gonzalez-Oria,
Universitary Hospital Virgen del Rocio, Seville, Spain

e-Poster 046       

BOTULINUM TOXIN TYPE-A TREATMENT IN CHRONIC CLUSTER HEADACHE: A CASE SERIES OF 19 PATIENT
L. Munoz-Delgado, R. Perez-Esteban, MD. Jimenez-Hernandez, MC. Gonzalez-Oria,
Universitary Hospital Virgen del Rocio, Seville, Spain
 
e-Poster 047       

EVALUATION OF CARDIOVASCULAR RISKS IN ADULT PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE TREATED WITH GALCANEZUMAB: DATA FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
Tina M. Oakes1, Richard Kovacs2, Noah Rosen3, Erin Doty1, Phebe Kemmer1, Sheena K. Aurora1, Angelo Camporeale4
1Eli Lilly and Company, Indianapolis, IN, USA, 2Indiana University, School of Medicine, Indianapolis, IN, USA, 3Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA, 4Eli Lilly Italia, Sesto Fiorentino, Italy
 
e-Poster 048       

A CASE OF SUPRAORBITAL NEURALGIA SUCCESSFULLY TREATED WITH PREGABALIN
Maria Koutsokera, Teresa Pasqua Acquaviva
Neurologic Department, "Thriassio" General Hospital, Elefsis, Greece

e-Poster 049       

PATIENT GAINS IN DAILY FUNCTIONING AND REDUCTIONS IN DISABILITY WITH GALCANEZUMAB AMONG PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE
Dustin Ruff1, Janet Ford1, Amaal Starling2, Holland Detke1, Russell Nichols1, Martha Port1, Sheena K. Aurora1
1Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA, 2Mayo Clinic, Scottsdale, AZ, USA
 
e-Poster 050       

ANTI-CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES: ADVERSE EFFECTS. WHERE DO WE STAND?
Theodoros Mavridis, Chrysoula Koniari, Breza Marianthi, Nikolaos Fakas, Dimos D. Mitsikostas
1st Neurology Department, Aeginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
 
e-Poster 051       

NO INCREASE IN BRAIN IRON CONTENT IN REFRACTORY CHRONIC MIGRAINE: A QUANTITATIVE SUSCEPTIBILITY MAPPING STUDY
Mi Ji Lee*1, Seulki Yoo*2,3, Soonwook Kwon1, Soohyun Cho1, Seung-Kyun Lee2,3, Chin-Sang Chung1
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea, 2Department of Biomedical Engineering, Sungkyunkwan University, Suwon 16419, South Korea, 3Center for Neuroscience Imaging Research, Institute for Basic Science (IBS), Suwon 16419, South Korea, *These two authors contributed equally.

e-Poster 052       

FUNCTIONAL CONNECTIVITY AND PHOTO-, PHONO-, OSMOPHOBIA IN MIGRAINE
Noboru Imai1, Asami Moriya1, Eiji Kitamura2
1Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Shizuoka, Japan, 2Department of Neurology, Kitasato University, Sagamihara, Kanagawa, Japan

e-Poster 053       

LONG TERM ACTIONS OF A RECOMBINANT ADVANCED BOTULINUM TOXIN (BITOX-AA) MOLECULE IN MIGRAINE ANIMAL MODELS
Ramla AbuukarAbdullahi1,2, Joseph O. Lloyd1, Martyn G Jones1, Giorgio Lambru2, Adnan Al-Kaisy3, Bazbek Davletov4, Anna P Andreou1,2*
1Headache Research, Wolfson CARD, King's College London, UK, 2Headache Centre, Guy's and St Thomas' NHS Trust, UK, 3Pain Management and Neuromodulation Centre, Guy's and St Thomas' NHS Trust, UK, 4Department of Biomedical Science, University of Sheffield, UK, *Email address of corresponding author: ramla

e-Poster 054       

A POSSIBLE ROLE FOR 2-AG IN THE “ADDICTION” ASPECT OF MEDICATION‐OVERUSE HEADACHE?
Rosaria Greco1, Marta Allena1, Chiara Demartini1, Anna Maria Zanaboni1,2, Elena Tumelero1; Daniele Piomelli3, Roberto De Icco1,2, Natascia Ghiotto1,  Grazia Sances1, Cristina Tassorelli1,2
1Headache Science Centre, IRCCS Mondino Foundation, Pavia, Italy, 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy, 3Deptartment of Anatomy and Neurobiology, University of California, USA

e-Poster 055       

OXIDE-DONOR GLYCERYL-TRINITRATE ADMINISTRATION FACILITATES SPINAL NOCICEPTIVE IN HIGH-FREQUENCY MIGRAINE
Roberto De Icco1,3, Armando Perrotta2, Mart Allena1, Daniele Martinelli1,3, Alessia Putortì1,3, Grazia Sances1, Giorgio Sandrini1,3, Cristina Tassorelli1,3
1 Headache Science Centre, IRCCS Mondino Foundation, Pavia, Italy, 2 Headache Centre, IRCCS Neuromed, Pozzilli, Italy, 3 Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

e-Poster 056       

ASSESSMENT OF THE EFFICACY OF ERENUMAB DURING THE OPEN-LABEL TREATMENT (13–24 WEEKS) OF SUBJECTS WITH EPISODIC MIGRAINE WHO FAILED 2–4 PRIOR PREVENTIVE TREATMENTS: RESULTS OF THE LIBERTY STUDY
Uwe Reuter1, Peter Goadsby2, Michel Lanteri-Minet3, Peggy Hours-Zesiger4, Chrystel Fernandes4, Michel Ferrari5, Jan Klatt4
1Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany, 2University of California, San Francisco, USA, 3Department of Pain, CHU Nice, FHU InovPain, Université Côte d'Azur, Nice, France, 4Novartis Pharma AG, Basel, Switzerland, 5Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands

e-Poster 057       

IS IT USEFUL TO DETERMINE CGRP, VIP, AND PACAP IN MIGRAINE? A CROSS-SECTIONAL STUDY IN CHRONIC MIGRAINE PATIENTS
Sara Pérez-Pereda1, María Toriello-Suárez1, Gonzalo Ocejo-Vinyals2, Sandra Guiral-Foz2, Jesús Castillo-Obeso3, Silvia Montes-Gómez3, Rosa Maria Martínez-Nieto3, Vicente González-Quintanilla1, Agustín Oterino-Durán1
1Neurology Service University Hospital Marqués de Valdecilla and IDIVAL. Cantabria. Spain, 2Inmunology Service University Hospital Marqués de Valdecilla. Cantabria. Spain, 3Primary Care Camargo Costa Health Center. Cantabria. Spain

e-Poster 058       

ABSENCE OF CLINICALLY SIGNIFICANT DRUG INTERACTIONS WITH COADMINISTRATION OF ATOGEPANT AND AN ETHINYL ESTRADIOL/LEVONORGESTREL ORAL CONTRACEPTIVE IN HEALTHY FEMALE SUBJECTS: A PHASE 1 PHARMACOKINETIC ANALYSIS
Wendy Ankrom, PhD1; Jialin Xu, PhD1; Marie-Helene Vallee, MSc1; Marissa F. Dockendorf, PhD1; Danielle Armas, MD2; Ramesh Boinpally, PhD3; K. Chris Min, MD, PhD1
1Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA, 2Celerion Inc., Phoenix, AZ, USA, 3Allergan plc, Madison, NJ, USA

e-Poster 059       

PROPHYLACTIC EFFECT OF ULTRAMICRONIZED N-PALMITOYL ETHANOL AMIDE (PEA) ON PEDIATRIC MIGRAINE
Laura Papetti1*, Giorgia Sforza1,2*, Giulia Tullo3, Samuela Tarantino1, Romina Moavero1,2, Fabiana Ursitti1, Michela Ada Noris Ferilli 1, Massimiliano Valeriani1,4.
1 Headache Center, Child Neurology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy, 2 Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, Italy,  3Pediatric Unit, Sant’Andrea Hospital, University Sapienza of Rome, II faculty,  4Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark Neurology Unit, *These authors have equally contributed.

e-Poster 060       

CYCLIC VOMITING SYNDROME AND BENIGN PAROXYSMAL TORTICOLLIS ARE ASSOCIATED WITH A HIGH RISK OF DEVELOPING PRIMARY HEADACHE: A LONGITUDINAL STUDY
Michela Ada Noris Ferilli 1, Romina Moavero1,2, Laura Papetti1, Maria Chiara Bernucci1, Caterina Cenci1, Giorgia Sforza2, Federico Vigevano1, Massimiliano Valeriani1,3
1Headache Center, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy, 2Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, Italy, 3Center for Sensory Motor Interaction Aalborg University, Aalborg, Denmark
 
e-Poster 061       

SYSTEMATIC REVIEW OF CLINICAL STUDIES EVALUATING NON-INVASIVE NEUROMODULATION DEVICES FOR MIGRAINE AND CLUSTER HEADACHE
Uwe Reuter1*; Candace McClure2; Eric Liebler3; Patricia Pozo-Rosich4,5
1Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany , 2North American Science Associates, Inc., Minneapolis, Minnesota, USA, 3electroCore, Inc., Basking Ridge, New Jersey, USA, 4Headache & Craniofacial Pain Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain, 5Headache Research Group, VHIR, Universitat Autònoma de Barcelona, Barcelona, Spain

e-Poster 062       

SYNERGISTIC BUT SEPARABLE SENSORY CHANGES IN MIGRAINEURS AND POSTURAL TACHYCARDIA SYNDROME
K.C. Brennan
 
e-Poster 064       

DRAMATIC RECOVERY IN A REFRACTORY CHRONIC S.U.N.C.T. AFTER THE IMPLANTATION OF AN OCCIPITAL NERVE STIMULATION DEVICE
Robert Belvís, Maria Jesús Alvarez, Marina Guasch, Eduard Juanola, Artur Izquierdo, Marta Caballero, Rodrigo Rodriguez.
Headache Unit. Department of Neurology, Hospital de la Santa Creu i Sant Pau, Functional Neurosurgery Unit. Department of Neurosurgery, Barcelona, Spain.

 

e-Poster Presentation Session 3: 
Observational, epidemiological and case studies

Chairs: Prof. Christian LamplProf. Evangelia Kararizou 

e-Poster 065       

TYPICAL AURA WITHOUT HEADACHE: A CASE SERIES OF 5 PATIENTS
Joanna Spanou, Konstantina Rizonaki, Georgios Liakakis, Anastasia Bougea, Sophia Xirou, Dimos-Dimitris Mitsikostas, Evangelina Kararizou
1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Greece

e-Poster 066       

THE RELATIONSHIP BETWEEN PRIMARY HEADACHES AND THYROID DISORDERS: A RETROSPECTIVE STUDY FROM A GREEK HEADACHE OUTPATIENT CLINIC
Joanna Spanou, Foteini Christidi, GGeorgios Liakakis, KKonstantina Rizonaki, Anastasia Bougea, Evangelos Anagnostou,  Evangelina Kararizou
1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Greece

e-Poster 067       

CLINICAL FEATURES OF CLUSTER HEADACHE PATIENTS IN RUSSIA
Anastasiia Savitskaia

e-Poster 068       

SLEEP CHARACTERISTICS AND PAIN SENSITIVITY IN EPISODIC AND CHRONIC MIGRAINE AND TENSION-TYPE HEADACHE (TTH) - A POPULATION STUDY
Angeliki Vgontzas, Suzanne Bertisch, Monika Haack, Rigmor Jensen, Lars Bendtsen, Richard B.Lipton, Sait Ashina

e-Poster 069       

THE ASSOCIATION BETWEEN OCCURRENCE OF MIGRAINE HEADACHE AND OBJECTIVELY-ASSESSED SLEEP AMONG ADULTS WITH EPISODIC MIGRAINE: A PROSPECTIVE COHORT STUDY
Angeliki Vgontzas, Wenyuan Li, Elizabeth Mostofsky, Murray A. Mittleman, Suzanne Bertisch
 
e-Poster 070       

A PARTICULAR CASE OF FACIAL PARAESTHESIAS DUE TO A MENINGIOMA
Angelo Torrente*, Concetta Rubino§
*Department of Biomedicine, Neurosciences and Diagnostic (Bi.N.D.), University of Palermo, Italy, Outpatient Neurological Clinic, P.T.A. “Biondo” A.S.P. Palermo, Italy

 e-Poster 071       

A REAL-WORLD ANALYSIS OF THE BURDEN OF MIGRAINE IN PATIENTS WITH PRIOR TREATMENT FAILURES: EVIDENCE FROM THE BECOME STUDY
Christian Lucas1, Patricia Pozo-Rosich2, David Watson3, Charly Gaul4, Emma Ramsden5, Shannon Ritter6, Paolo Martelletti7, Josefin Snellman5
1Pain Clinic, Service de Neurochirurgie, Hôpital Salengro, CHRU de Lille, Lille Cedex, France, 2Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, and Headache and Neurological Pain Research Group, Vall d’Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain, 3Hamilton Medical Group, Aberdeen, Scotland, 4Migraine and Headache Clinic Königstein, Königstein im Taunus, Germany, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa, Rome, Italy

e-Poster 072       

BACKSTAGE HERO OF CHRONICITY IN MIGRAINE NATUREL HISTORY: CO MORBIDITY
Ayşe Begüm Büyüksural 1, Aynur Özge 2, Didem Derici Yıldırım 3, Bahar Taşdelen 3
1-2 Mersin University Faculty of Medicine, Department of Neurology, Mersin, Turkey, 3 Mersin University Faculty of Medicine, Department of Biostatistic, Mersin, Turkey
 
e-Poster 073       

LOSS OF CONSCIOUSNESS AND CHRONIC POST-TRAUMATIC HEADACHE.
Brad Torphy
Diamond Headache Clinic, Chicago, IL, USA Hayley Bemel, Argosy University, Chicago, IL, USA

e-Poster 074       

MANAGEMENT OF MEDICATION-OVERUSE HEADACHE; A PRACTICAL GUIDE
Christofer Lundqvist
 
e-Poster 075       

CLINICAL CHARACTERISTICS OF HEMIPLEGIC MIGRAINE: A CLINICAL STUDY OF 31 CASES IN JAPAN
Daisuke Danno1, Johanna Wolf2, Kazumasa Saigo3, Shigekazu Kitamura4, Kumiko Ishizaki1, Junichi Miyahara1, Shoji Kikui1, Hiroo Yoshikawa2, Takao Takeshima1
1Headache center, Tominaga hospital, Osaka, Japan, 2Division of Neurology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan, 3Department of Life Science, Faculty of Science and Engineering, Kindai University, Osaka, Japan, 4Department of Neurology, Konan Hospital, Hyogo, Japan

e-Poster 076       

IMPACT OF MEDICAL CARE ON SYMPTOMATIC DRUG CONSUMPTION AND QUALITY OF LIFE IN HEADACHE PATIENTS : A ONE YEAR POPULATION STUD
F. Antonaci1, M. Cotta Ramusino1, N. Vanacore2, A. Costa1
1Department of Brain and Behavioral Sciences, C. Mondino National Institute of Neurology Foundation, IRCCS, University of Pavia, Pavia, Italy, 2 National Centre for Epidemiology, Surveillance, and Health Promotion, National Institute of Health, Rome, Italy
 
 e-Poster 077       

COGNITIVE FUNCTIONS IN MIGRAINEURS WITH AND WITHOUT AURA
Konstantinos Kampouris1, Dimitrios Kasselimis2, Dimos D. Mitsikostas3, Constantin Potagas3
1MSc Clinical Neuropsychologist, Neuropsychology and Rehabilitation Unit for Brain Injury, ELEPAP, Ioannina, Greece, 2Neuropsychology and Language Disorders Unit, 1st Neurology Department, Aiginiteion Hospital, National & Kapodistrian University of Athens, Greece, 3Associate Professor of Neurology, 1st Neurology Department, Aiginiteion Hospital, National & Kapodistrian University of Athens, Greece
 
e-Poster 078       

THE PREVALENCE OF PRIMARY HEADACHE DISORDERS IN ESTONIA
Kati Toom1,2, Aire Raidvee3, Katri-Helena Allas4, Elina Floria4, Kristiina Juhkami4, Gustav Klimušev4, Maria Leping4, Margot Liidemann4, Alexander Milovidov4, Karita Liivak4, Siiri Paiste4, Gerli Paju4, Karel Uhs4, Marge Vaikjärv4, Kristiina Veetõusme4, Priit Välja4, Mark Braschinsky1,2
1Neurology Clinic, Tartu University Hospital, Tartu, Estonia, 2Estonian Headache Society, Tartu, Estonia, 3Institute of Psychology, University of Tartu, Tartu, Estonia, 4Faculty of Medicine, Tartu University, Tartu, Estonia

e-Poster 079       

HEADACHE AND SLEEP DISORDERS 
E.Giannouli, V. Sakkou, A. Athanasouli, Th. Kalamatas, A. Kargadou, K.E. Karageorgiou
Neurology Dept., Athens Medical Center, Greece

e-Poster 080       

PROPOSED TREATMENT FOR MEDICATION OVERUSE HEADACHE
A. Kargadou, E. Giannouli, A. Athanasouli, V. Sakkou, Th. Kalamatas, K.E. Karageorgiou
Neurology Dept., Athens Medical Center, Greece
 
e-Poster 081       

CLUSTER HEADACHE AND RESPONSE TO INDOMETHACIN
A. Athanasouli, E. Giannouli, A. Kargadou, Th. Kalamatas, K.E. Karageorgiou
Neurology Dept., Athens Medical Center, Greece

e-Poster 082       

SPONTANEOUS INTRACRANIAL HYPOTENSION PRESENTING AS MIGRAINE: A CASE REPORT
E. Giannouli, A. Athanasouli, A. Kargadou, Th. Kalamatas, K.E. Karageorgiou
Neurology Dept., Athens Medical Center, Greece
 
e-Poster 083       

PATIENTS PRESENTING WITH HEADACHE AS A MAIN COMPLAINT IN A SPECIAL NEUROLOGY DEPARTMENT
E. Giannouli, A. Athanasouli, A. Kargadou, Th. Kalamatas, K.E. Karageorgiou
Neurology Dept., Athens Medical Center, Greece
 
e-Poster 084       

THE EFFECT OF CONSULTING A SPECIALLY TRAINED HEADACHE NURSE ON THE QUALITY OF LIFE OF HEADACHE PATIENTS: CONTROLLED PROSPECTIVE INTERVENTIONAL STUDY
Kristi Tamela1,2, Mark Braschinsky1,2
1Neurology Clinic, Tartu University Hospital, Tartu, Estonia, 2Estonian Headache Society, Tartu, Estonia
 
e-Poster 085       

HEMIPLEGIC MIGRAINE WITH LATE-ONSET CEREBELLAR SIGNS AS PHENOTYPIC VARIANT OF CANCA1A MUTATION. CASE REPORT
EirinI Giagkou, Marianthi Breza, Vasileios Natsis, Theodora Mavridis, Argyro Tountopoulou, Sofia Vassilopoulou, Dimos Dimitrios Mitsikostas
1st Neurology Department, Eginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
 
e-Poster 086        

SYNDROME OF TRANSIENT HEADACHE AND NEUROLOGICAL DEFICITS WITH CEREBROSPINAL FLUID LYMPHOCYTOSIS (HANDL): A DIAGNOSIS BY EXCLUSION. CASE REPORT
Theodoros Mavridis, Alexandra Akrivaki, Chrysoula Koniari, Panagiota Kardara, George Stouraitis, Nikolaos Fakas
401 General Military Hospital of Athens, Neurology Department, Athens, Greece
 
e-Poster 087       

DYSPHASIA AND OTHER HIGHER CORTICAL DYSFUNCTIONS DURING THE MIGRAINE AURA - A SYSTEMATIC REVIEW OF LITERATURE
Igor Petrusic1, Michele Viana 2,3*, Chiara Zecca,2, Jasna Zidverc-Trajkovic 4,5
1 Laboratory for advanced analysis of neuroimages, Faculty of Physical Chemistry, University of Belgrade, Serbia, 2 Headache Center, Institute of the Neurocenter of Southern Switzerland (NSI), Regional Hospital Lugano, Lugano, Switzerland, 3 Headache Group, Department of Basic and Clinical Neurosciences, King's College London, London, UK, 4 Center for headaches, Neurology Clinic, Clinical Center of Serbia, 5 Faculty of Medicine, University of Belgrade, Serbia

e-Poster 088       

HEADACHE AND BRAIN VASCULAR MALFORMATIONS: PITFALLS IN THE DIAGNOSTIC
Olena Tsurkalenko, Lyudmyla Dzyak
SI "Dnipropetrovsk medical akademy", Dnipro, Ukraine

e-Poster 089       

HEADACHE FAST TRACK FROM THE EMERGENCY ROOM
Cristiano Maria De Marco1, Martina Guglielmetti1,2, Andrea Negro3, Paolo Martelletti1,3
1Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy, 2University of Sassari, Sassari, Italy, 3 Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy

e-Poster 090       

CONTENT VALIDITY OF THE HIT-6 IN MIGRAINE PATIENTS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW
Carrie R. Houts1, RJ Wirth1, James S. McGinley1, Chad Gwaltney2, Roger Cady3
1Vector Psychometric Group, LLC, Chapel Hill, NC, USA, 2Gwaltney Consulting, Westerly, RI, USA, 3Alder BioPharmaceuticals, Inc., Bothell, WA, USA

e-Poster 091       

CHRONIC MIGRAINE: ESTABLISHING A RESPONDER DEFINITION FOR THE HIT-6 TOTAL SCORE
Roger Cady1, RJ Wirth2, James S. McGinley2, Carrie R. Houts2, Jeff Smith3
1Alder BioPharmaceuticals, Inc., Bothell, WA, USA, 2Vector Psychometric Group, LLC, Chapel Hill, NC, USA ,  3Alder BioPharmaceuticals, Ltd., Dublin, Ireland

e-Poster 092       

UNDIAGNOSED CHRONIC MIGRAINE IS ASSOCIATED WITH HIGHER ECONOMIC BURDEN COMPARED WITH DIAGNOSED CHRONIC MIGRAINE: RESULTS FROM A CLAIMS-BASED RETROSPECTIVE STUDY
Steven C. Marcus1, Anand R. Shewale2, William B. Young3, Justin S. Yu2, Jelena M. Pavlovic4, Hema N. Viswanathan2, Jalpa A. Doshi1
1University of Pennsylvania, Philadelphia, PA, USA, 2Allergan plc, Irvine, CA, USA, 3Thomas Jefferson University, Philadelphia, PA, USA, 4Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA

e-Poster 093       

PROTECTIVE ROLE OF FRUIT AND VEGETABLE AGAINST PEDIATRIC MIGRAINE HEADACHE: A CASE- CONTROL STUDY
Soodeh Razeghi Jahromi1,2, Shadi Ariyanfar1,2, Nasim Rezaeimanesh 3,1, Mansoureh togha 2*,   Zeinab ghorbani2,4, Ebrahim khadem5
1Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran, 3 Multiple sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran, 4 School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran, 5 School of Iranian Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran

e-Poster 094       

FACTORS REDUCING DEPRESSIVE SYMPTOMS IN DEPRESSED MIGRAINE PATIENTS
Sung-Pa Park
Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea
 
e-Poster 095       

EXCESSIVE DAYTIME SLEEPINESS IN TENSION-TYPE HEADACHE: A POPULATION-BASED STUDY
Tae-Jin Song1, Kyung Min Kim2, Dong Hyun Lee2, Won-Joo Kim3, Soo-Jin Cho4, Kwang Ik Yang5, Chang-Ho Yun6, Min Kyung Chu2
1 Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, 2 Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, 3 Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, 4 Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea, 5 Department of Neurology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Korea, 6 Department of Neurology, Bundang Clinical Neuroscience Institute, Seoul National University Bundang Hospital, Seongnam, Korea

e-Poster 096       

POOR SLEEP QUALITY IN TENSION-TYPE HEADACHE: A POPULATION-BASED STUDY
Tae-Jin Song, MD1; Kyung Min Kim MD2, Soo-Jin Cho, MD, PhD2; Won-Joo Kim, MD, PhD3; Kwang Ik Yang, MD, PhD4; Chang-Ho Yun, MD, PhD5; Min Kyung Chu, MD, PhD1
1Department of Neurology, Ewha Womans University College of Medicine, 2Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea, 3Department of Neurology, Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea, 4Department of Neurology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Korea, 5 Department of Neurology, Bundang Clinical Neuroscience Institute, Seoul National University Bundang Hospital, Seongnam, Korea

e-Poster 097       

IS PEDIATRIC MEDICATION OVERUSE HEADACHE REALLY DUE TO MEDICATION OVERUSE?
Romina Moavero, Maddalena Stornelli, Laura Papetti, Barbara Battan, Samuela Tarantino, Federico Vigevano, Massimiliano Valeriani
Headache Center, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

e-Poster 098       

ROLE OF MATERNAL STRESS AND ALEXITHYMIA IN CHILDREN’S MIGRAINE SEVERITY AND PSYCHOLOGICAL PROFILE
Samuela Tarantino*1, Alessandra di Stefano1, Valeria Messina1, Laura Papetti2, Michela Ferilli2, Giorgia Sforza3, Fabiana Ursitti2, Romina Moavero2, Federico Vigevano2, Simonetta Gentile1,Massimiliano Valeriani2,4
1Unit of Clinical Psychology, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza Sant’Onofrio 4, Rome, Italy, 2Headache Center, Division of Neurology, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza Sant’Onofrio 4, Rome, Italy, 3Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, 4Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark

e-Poster 099       

DEPRESSION AND ANXIETY LIKE SYMPTOMS IN PRIMARY HEADACHE DISORDERS
M. Lypiridou, I. Belesioti, C. Deligianni, E. Mitropoulou, E. Kasioti, D.D. Mitsikostas
First Neurology Department, Aeginition Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece

e-Poster 100       

TYPICAL MIGRAINE AURA WITHOUT HEADACHE IN KOREAN HEADACHE CLINIC
Byung-Kun Kim
Department of Neurology, Eulji Hospital, Seoul, Korea

e-Poster 101       

USE OF A DIGITAL PLATFORM IN HEADACHE TRAINING. STRENGTHS AND WEAKNESSES IN 5 YEARS
Luca Maria Messina, Vincenzo Raieli
Child Neuropsychiatry Unit - ISMEP - ARNAS Civico Palermo, Italy

e-Poster 102       

ONE-YEAR EXPERIENCE OF ANAESTHETIC BLOCKADES IN A HEADACHE UNIT
Robert Belvís, Marina Guasch, Eduard Juanola, Artur Izquierdo, Marta Caballero,
Headache Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain